Skip to content

Precision fermentation / Evidence map 01

The bottleneck is not another protein model

It is knowing which host, construct, process, purification route and evidence gap deserve the next experiment. Kairos turns that chain into an auditable decision record before wet-lab and CDMO spend.

01SpecifyProduct + constraints
02Host fitEvidence, not rank
03DesignConstruct + risks
04TestMeasured readout
05CompileProcess + DSP + TEA
06LearnProduction feedback

01 / Market reality

A real market, not yet a predictable software market

Commercial estimates point to rapid growth. Operational evidence points to a harder truth: projects still fail on cost, capability fit, scale-up and unit economics. Both facts matter.

163+specialized fermentation companies identified in GFI's 2025 industry report
$357Mfermentation investment in 2025, down from $632M in 2024
$6.4B2026 broad-market estimate; scope is wider than Kairos's serviceable decision layer
3,000 Lone reported continuous-fermentation demonstration, not a cross-product validation
M1

Cost is the adoption gate

Scaling alone is not enough. Feedstock, host productivity, process intensity, DSP and capital efficiency have to improve together. Synthesis Capital, 2025.

M2

Capacity is not the same as capability

Host, scale, food-grade or pharma-grade operation, DSP and analytics must match the product. A list of tanks is not a manufacturing plan. GFI / Integration Consulting.

M3

Capital has become more selective

GFI reports a smaller 2025 fermentation funding pool, high-profile closures and a shift toward unit economics and credible paths to profitability.

M4

Data is still fragmented

The industry has called for standardized bioprocess data and further precision-fermentation TEA modelling. More text does not fix a missing input.

M5

CROs and engineering platforms already sell execution

Kairos cannot compete by saying it is "AI-powered." It must improve the pre-execution decision and hand off a record a lab or CDMO can act on.

M6

The market estimate is context, not TAM

A broad precision-fermentation forecast bundles products, ingredients and business models. It does not establish willingness to pay for a decision dossier.

Market figures are shown with their scope. The $6.4B estimate is from a commercial research summary and should not be treated as Kairos revenue potential.

02 / Scientific evidence

The host is not the answer
The fit is

Published data supports several hosts for several products. It does not support one universal winner, one universal process or an extrapolated titer for a new protein.

Scroll the table horizontally to compare hosts.

HostEvidence that mattersWhy it can winWhat remains gated
Komagataella phaffii
Pichia
Mature industrial secretion host. Recombinant ovomucoid reported at 3.2 g/L in a 2025 egg-protein review.Secretory expression, high-cell-density fed-batch, eukaryotic processing and a deep industrial record.Product-specific Proteolysis, PTMs, induction and DSP must be measured for the target.
Trichoderma reeseiβ-lactoglobulin at 1 g/L and ovalbumin at 2 g/L in a peer-reviewed bioreactor study; strong native secretion can also complicate purification.High secretory capacity and existing industrial enzyme infrastructure.Scale gate Host-protein background, proteases and product function.
E. coliOvalbumin reported at 3.7 g/L at laboratory scale.Fast growth, simple genetics and established manufacturing economics.Fit gate No eukaryotic PTMs; folding, function and endotoxin constraints.
Other yeasts / fungiActive research across Kluyveromyces, Ogataea, Saccharomyces and filamentous fungi.Food heritage, non-methanol routes or alternative secretory behaviour.Evidence gap Tool maturity, product-specific yield and industrial process depth.
S1

Cost-efficient food protein usually requires tens of grams per litre

A 2024 Annual Review frames above 50 g/L as a directionally useful production threshold, several orders of magnitude above many pharma processes. It is not a promise for any individual construct.

S2

Egg proteins are still early

A 2025 review found only six egg proteins reported at laboratory scale. PTM, functionality, cost parity and the whole upstream-to-DSP chain remain unresolved.

S3

Fed-batch is a control problem

Methanol feeding, co-substrate, induction intensity, oxygen transfer, pH and cell density interact. "Use high-cell-density fermentation" is not a transferable protocol.

S4

Food-grade DSP should preserve function

Chromatography designed for high-value biologics can be the wrong cost structure. Alternative food-grade methods are promising, but many remain at the conceptual stage.

S5

One lab result is not a process

A 26 to 72 wt% protein enrichment for β-lactoglobulin with polyphosphate is useful evidence. It is not a universal DSP route or an economic guarantee.

S6

The right output is a question, a route and a gap

Kairos should return comparable evidence, process constraints and the next decisive experiment. It should not return an unexplained "best construct."

03 / Process evidence

Every step changes the next one

A precision-fermentation dossier has to preserve the couplings. Changing the signal peptide, feed strategy or purification step can change titer, purity, function and cost at the same time.

01 / SPEC

Define product and process constraints

Protein, product form, purity or function target, food or pharma use, dose, geography, scale, budget and unacceptable route.

Out: decision brief + stopping criteria

02 / HOST

Test host fit against the product

Secretory capacity, PTMs, protease background, codon use, high-cell-density evidence, regulatory precedent and manufacturing maturity.

Out: host evidence matrix + unknowns

03 / DESIGN

Design the construct and process together

Signal peptide, promoter, gene dosage, secretion route, induction and likely proteolytic or glycosylation liabilities.

Out: ranked candidates + audit

04 / TEST

Turn the decision into an experiment

Controls, acceptance criteria, assay, sample plan, owners and a structured result schema. Failure must return to the record.

Out: executable test package

05 / COMPILE

Compile upstream, DSP and economics

Feed and oxygen transfer, harvest, recovery, purification, function, analytical burden, TEA ranges and missing inputs.

Out: process route + WARN register

06 / LEARN

Use production to revise the decision

Batch conditions, deviations, QC, release evidence and failures become evidence for the next construct, process and partner choice.

Out: calibrated next decision

04 / Kairos product

Process Decision Dossier

A governed evidence record for the decisions made before a production batch exists. Reviewed claims retain provenance. Relevant missing inputs remain visible. Recommended experiments record their rationale.

01

Specify and audit

Pichia-scoped decision brief, candidate design and claim-level evidence audit.

Available scope
02

Expose process uncertainty

Directional DSP and TEA intelligence with explicit WARNs and missing fields.

Partial
03

Close the wet-lab loop

Experiment schema, result backfill and failure attribution tied to the original decision.

Next gate
04

Compile a pilot package

Process evidence, analytical plan, partner requirements and scale-risk record.

Gated
05

Learn from production

Batches change the next decision. The system earns this stage only through repeated production use.

Destination

05 / Validation

Seven gates before this becomes a platform

The narrative should rise only when evidence rises. These gates keep the product honest and make the commercial proof falsifiable.

G1Problem

10 real interviews show a costly, recurring selection problem.

G2Evidence

Three dossiers have traceable claims, scope and explicit WARNs.

G3Decision

One pre-registered metric beats the customer's baseline.

G4Payment

Customers pay for the pre-wet-lab dossier itself.

G5Execution

A lab can run the package and deviations are attributable.

G6Learning

Returned results improve ranking, uncertainty or abstention.

G7Repeat

Two customers return and one CRO/CDMO accepts joint delivery.

Evidence boundary

What this page refuses to claim

  • That one host is universally best for dairy, egg and industrial proteins.
  • That a literature titer transfers to a new construct, process or facility.
  • That food-grade and high-purity pharma DSP share the same cost structure.
  • That a host-level GRAS history approves every product made by that host.
  • That the production learning loop already exists before prospective batch feedback.

Keep the route open only as long as the evidence keeps the gate open.

Start with a decision brief
Sources, dates and evidence grades
  1. [C] Grand View Research, Precision Fermentation Market, 2026-2033, updated 2026-10-23.
  2. [B] GFI, State of the Industry: Fermentation, 2025.
  3. [B] GFI and Integration Consulting, Fermentation manufacturing capacity analysis.
  4. [B] GFI and Hawkwood Biotech, Techno-economic insights on fermentation ingredients, 2025-06-10.
  5. [B] Synthesis Capital, Precision Fermentation: Pathways to Cost Parity, 2025-08-01.
  6. [A] The Next Food Revolution Is Here, Annual Review of Food Science and Technology, 2024.
  7. [A] Industrial Production of Proteins with Pichia pastoris-Komagataella phaffii, PMID 36979376.
  8. [A] Fed-batch high-cell-density fermentation strategies for Pichia pastoris, PMID 30599783.
  9. [A] Production of bovine beta-lactoglobulin and hen egg ovalbumin by Trichoderma reesei, PMID 36596092.
  10. [A] Building a Versatile Protein Production Platform Using Engineered Trichoderma reesei, PMID 34928572.
  11. [A] Scientific and technological challenges of recombinant egg protein production, PMID 40604696.
  12. [A] Simple purification of recombinant beta-lactoglobulin using polyphosphate, PMID 38163711.
  13. [A] Downstream Processing of Food Proteins from Precision Fermentation, 2026.
  14. [A] Innovation in precision fermentation for food ingredients, PMID 36640107.
  15. [A] FDA, GRAS Notice 1201 and GRAS Notice 1290.